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Abstract
Purpose of review—Understanding the interplay between myeloid dendritic cells and T cells
under tolerogenic conditions, and whether their interactions induce the development of antigen-
specific regulatory T cells (Tregs) is critical to uncover the mechanisms involved in the induction
of indefinite allograft survival.
Recent findings—Myeloid dendritic cell–T-cell interactions are seminal events that determine
the outcome of the immune response, and multiple in-vitro protocols suggest the generation of
tolerogenic myeloid dendritic cells that modulate T-cell responses, and determine the outcome of
the immune response to an allograft following adoptive transfer. We believe that identifying
specific conditions that lead to the generation of tolerogenic myeloid dendritic cells and Tregs are
critical for the manipulation the immune response towards the development of transplantation
tolerance.
Summary—We summarize recent findings regarding specific culture conditions that generate
tolerogenic myeloid dendritic cells that induce T-cell hyporesponsiveness and Treg development,
and represents a novel immunotherapeutic approach to promote the induction of indefinite graft
survival prolongation. The interpretations presented here illustrate that different mechanisms
govern the generation tolerogenic myeloid dendritic cells, and we discuss the concomitant
therapeutic implications.
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Introduction
A major challenge in transplantation is to control the strong immune responses to foreign
antigens that are responsible for graft rejection. Although immunosuppressive drugs
efficiently inhibit acute graft rejection, a substantial proportion of patients suffer chronic
rejection leading to functional loss of the graft. Induction of immunological tolerance
constitutes more than just a laboratory solution for the need of lifelong treatment with
immunosuppressive drugs for transplant recipients [1], and immunotherapy with myeloid
dendritic cells and their precursors represent a promising tool for the establishment of
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indefinite allograft survival [2] Over the last years there have been an increasing number of
articles that manipulated myeloid dendritic cell precursors to influence the immune response
towards tolerance. Some of these articles also investigated the induction of antigen-specific
tolerance using particular in-vitro culture conditions that cause T-cell hyporesponsiveness
and promote regulatory T-cell (Treg) development. We have reviewed numerous strategies
that are available to generate stable myeloid dendritic cells with tolerogenic properties,
which include their modification with chemicals [3], cytokines [4], peptides [5]; via gene
modification [6], small interfering RNA [7], and immunosuppressive drugs [8], some of
which have already given promising results in macaques [9].
Generation of tolerogenic myeloid cells in vitro
Immunosuppressants
Rapamycin—Most of the experimental research with rapamycin conditioned dendritic
cells for the induction of transplantation tolerance comes from Angus Thomson laboratory,
which initially reported that rapamycin-treated alloantigen-pulsed dendritic cells infused 1
week before transplantation inhibits antigen-specific T-cell responsiveness and prolongs
skin graft survival [10]. Similar studies reported indefinite vascularized skin allograft
survival in recipient rats treated with antilymphocyte serum and cyclosporine, together with
rapamycin-conditioned dendritic cells cultured with donor-derived peptide [11].
Interestingly, T cells from long-surviving grafts in these mice exhibit donor-specific
hyporesponsiveness and expression of Foxp3 [11], which is consistent with a recent study
which suggests that inhibition of mammalian target of rapamycin (mTOR) signaling during
T-cell activation by rapamycin induces foxp3 in synergy with TGF-β [12].
Mycophenolic acid—Human dendritic cells cultured with granulocyte-macrophage
colony-stimulating factor (GM-CSF), IL-4, TNF-α, and mycophenolic acid (MPA) results in
the generation of alloantigen-specific and contact-dependent suppressive Foxp3-expressing
Tregs that secreted large amounts of IL-10 and TGF-β, and have high expression of CD25,
glucocorticoid-induced tumor necrosis factor receptor (TNFR) [GITR], CTLA-4, and CD95
[13].
Cyclosporine A—It has been recently proposed that cyclosporine A increases the
production of IL-10 in dendritic cells, and inhibits dendritic cell allostimulatory capacity by
up-regulating B7 expression [14].
Dexamethasone—Human myeloid dendritic cells cultured with GM-CSF,
dexamethasone, and lipopolysaccharide (LPS) produce high levels of IL-10 and reduces Th1
cytokine production [15]. Likewise, dexamethasone-stimulated human monocytes become
tolerogenic dendritic cells that stimulate CD4+ T lymphocytes to become Treg, which inhibit
antigen-specific immune responses by secreting IL-10 [16]. In rats, in-vitro generated
dendritic cells cultured with GM-CSF, IL-4, and dexamethasone bone marrow cells expand
Treg, whereas human blood monocytes cultured with GM-CSF, IL-4, dexamethasone, and
LPS induce T-cell anergy [17]. With regards to transplantation, donor hyporesponsive
dendritic cells can be generated from rat bone marrow cells with GM-CSF, IL-4, and Flt3L
in the presence of dexamethasone and LPS, although they do not prolong fully allogeneic
allograft survival [18].
Prostaglandin—Dendritic cells generated in the presence of GM-CSF, IL-2, and
prostaglandin are more efficient than anti-CD3/CD28 mAbs in expanding Treg and prevent
unwanted immune reactions to allografts, since only infusion of dendritic cell-expanded
Treg suppresses recipient response to donor alloantigens [19].
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Vitamin D3—Vitamin D3 (VD3)-matured dendritic cells are able to convert CD4+ T cells
into IL-10-secreting antigen-specific Tregs that suppress proliferation of effector T cells
[20]. When combined with LPS, human monocyte cultured in the presence of GM-CSF,
IL-4, VD3, and dexamethasone generates tolerogenic dendritic cells that retain a semimature
phenotype with an anti-inflammatory cytokine profile, which is important for optimizing
their therapeutic potential [21]. This is of special interest, since some of the critical aspects
for immunotherapy with myeloid cells suggest that tolerogenic dendritic cell maturation
must be impaired, specially during potential infections or inflammatory episodes following
their adoptive transfer [22,23]. With regards to the effects of VD3 on T cells, it has been
recently suggested that VD3 induces a transient expression of CTLA-4 and FoxP3 in
cultured human CD4+CD25– T cells, which may be used to modulate the immune response
[24].
Aspirin—Aspirin-treated human dendritic cells are resistant to maturation and exhibit a
reduced expression of co-stimulatory molecules, such as CD40, CD80, and CD86, and
increased expression of immunoglobulin-like transcript-3 (ILT3), which induces de-novo
generation of Treg and promotes transplantation tolerance [3]. This is consistent with
previous data, which suggest that tolerogenic myeloid cells must express low levels of cell-
surface coestimulatory molecules to regulate the immune response [25].
Aryl hydrocarbon receptor—Recipient-derived mouse bone marrow cells cultured in
the presence of GM-CSF, LPS, and an activator of the aryl hydrocarbon receptor, prevents
islet allograft rejection by reducing antigen specific T-cell responses in the draining lymph
node [26].
Interleukins/cytokines
Pioneer studies from Austin and colleagues suggested that low doses of GM-CSF in the
absence of IL-4 generates allogeneic immature dendritic cells in vitro that are resistant to
different maturation stimuli, induce T-cell unresponsiveness in vitro, and promote
alloantigen-specific graft acceptance [27]. Similarly, human monocytes cultured with GM-
CSF in the absence of IL-4 generate semimature myeloid cells with low stimulatory activity
[28]. Similarly, Torres-Aguilar and colleagues [4] have recently reported different ways of
generating tolerogenic dendritic cells from culturing human monocytes with GM-CSF and
IL-4 simultaneously with IL-10 ± IL-6 ± TGF-β1, which enhanced the expression of the
regulatory molecules, and induced strong antigen-specific anergy in memory T cells. Others
have suggested that GM-CSF, IL-4, and IFN-γ human monocytes develop into maturation-
resistant dendritic cells that express DC-SIGN, Langerin, and CD123, and promote
nonspecific Treg development [29]. With regards to transplantation, alloantigen-activated
CD4+ T cells cultured in the presence of IFN-γ promotes the generation of
CD25+CD62L+Foxp3+ T cells capable of preventing allograft rejection following adoptive
transfer [30,31]. Semimature dendritic cells generated from murine bone marrow
progenitors cultured with GM-CSF, IL-4, TNF-γ, and LPS, secrete low levels of IL-6 and
IL-12p70, induce effector T-cell hyporesponsiveness in vitro, expand Foxp3+ Treg in vivo,
prolonging skin allograft survival [32]. Murine bone marrow cells cultured with GM-CSF,
IL-10, and LPS generates alternatively activated donor dendritic cells that express high
levels of PD-L1, display a reduced alloreactive T-cell-stimulating capacity, and expand
Foxp3+ Treg in vitro, prolonging skin allograft survival [33•]. More recently, Thomson and
colleagues reported that coculture of Treg with immature donor-derived dendritic cells in
medium with GM-CSF and IL-4, induces potent alloantigen-specific Treg that prolong more
than 80% over 150 days cardiac graft survival in mice when combined with low-dose
rapamycin [34], which suggest a feedback loop between myeloid dendritic cells and Tregs
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[35]. In rats, immature dendritic cells cultured with GM-CSF and donor cell lysates are able
to induce peripheral immune tolerance to hind limbs when combined with rapamycin and
antilymphocyte serum [36]. Syngeneic adherent rat bone marrow cells cultured in the
presence of GM-CSF express high levels of HO-1, are poor stimulators of allogeneic T cells,
and prolonged cardiac allograft survival [37•].
Proteins–peptides
Vasoactive intestinal peptide—Vasoactive intestinal peptide (VIP) generates anergic T
cells by inducing cell cycle arrest and inhibiting cytokine production in allogeneic human T
cells. VIP also generates Foxp3-expressing Treg from CD4+CD25− T cells after allogeneic
stimulation, which exerts a protective role in a mouse model of acute graft-versus-host
disease (GvHD) [38]. Interestingly, dendritic cell differentiated in the presence of VIP
generates IL-10-secreting CD4+ and CD8+ T cells [39], and impair allogeneic antigen-
specific responses of donor CD4+ T cells in mice receiving bone marrow transplants by
inducing Treg in the graft [40].
Low-dose peptide—Turner and colleagues [41] recently reported that both, GM-CSF
derived immature dendritic cells, and GM-CSF and IL-4-derived mature dendritic cells
presenting low dose of antigen expands Foxp3+ Treg, which depends on IL-6 production
following dendritic cell–T-cell interactions.
Viral induced molecules
Pioneer studies from Cattral and colleagues demonstrated that transfection of donor-derived
bone marrow derived dendritic cells with FasL-induced hyporesponsiveness to alloantigen
in vivo and prolonged 15 days the graft survival of fully mismatched cardiac allografts [42].
In mice, donor-derived dendritic cells transfected with recombinant adenovirus encoding
human CTLA4Ig reduces the allogeneic T-cell stimulation in vitro, and prolongs cardiac
allograft survival for 40 days when injected intravenously [43]. George and colleagues
demonstrated that transfecting human dendritic cells with CTLA4 fused to the endoplasmic
reticulum retention signal sequence induces antigen-specific anergy in responding T cells by
preventing dendritic cell expression of CD80 and CD86 in the cell surface [6]. One of the
most promising results uses donor-derived immature dendritic cells transfected to express
soluble TNF receptor are resistant to maturation, which are unable to present antigen due to
their low phagocytic properties, promote the development of IL-10 regulatory T cells in
vitro, and induce long-term survival of cardiac allografts of 50% of the grafts when
transferred before transplantation without further treatment [44]. The same laboratory, also
investigated the induction of tolerance with IL-10 dendritic cell gene transfection, although
only 30-day graft survival prolongation was observed [45]. Several studies by Vassalli and
colleagues reported that gene transfer of programmed death ligand-1 Ig, indoleamine 2,3-
dioxygenase, and soluble IL-1R Ig fusion protein, and IL-18 binding protein to donor
dendritic cells attenuates cardiac allograft rejection and prolongs cardiac allograft survival
by 1 week [46–48]. More recently, lentiviral vectors have been used to genetically engineer
VIP-expressing bone marrow-derived dendritic cell which reduces dendritic cell expression
of proinflammatory cytokines and increases their IL-10 production following local delivery
[49].
Immunoglobulins
Human dendritic cells generated in vitro in presence of CTLA4-Ig suppress T-cell
proliferation by up-regulating the levels of HLA-G5 in plasma of CTLA4-Ig-treated
patients, with the concomitant immunosuppressive applications [50].
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There is also a great interest in manipulating the immune response using myeloid cells
derived from stem cell progenitors in vitro. Human embryonic stem cells (ESCs) cultured
with bone morphogenetic protein-4, GM-CSF, stem cell factor and vascular endothelial
growth factor (VEGF) in serum-free media generates hESC-derived monocytic cells that can
be further differentiated mature dendritic cells with GM-CSF, TNF-alpha, IL-1β, IFN-γ and
PGE2 that generates unlimited numbers of immunogenic dendritic cells [51]. Chen and
colleagues have recently reported a protocol to generate myeloid-derived suppressive cells
from murine embryonic stem cells in a three-step differentiation strategy which generated
embryonic bodies from HoxB4-transduced ESCs cultured with c-kit ligand conditioned
medium, IL-6, and WEHI-3, followed by c-kit ligand conditioned medium, thrombopoietin,
VEGF, and Flt-3L. The resulting myeloid-derived suppressor cells exhibited a strong
suppressive capacity in vitro, and was able to induce indefinite allograft survival of
allogeneic bone marrow transplants [52•].
Generation of tolerogenic myeloid cells in vivo
One potential risk of immunotherapy with tolerogenic dendritic cells generated in vitro is
that they may switch to a T-cell-activating phenotype when encountering inflammatory
signals in vivo, since the local microenvironment plays an important role in the modulation
of dendritic cells [53]. Complex myeloid dendritic cell–T-cell interactions occur in defined
micro-anatomic domains within secondary lymphoid organs that lead either to successful T-
cell priming or T-cell unresponsiveness, due to regulatory mechanisms that include anergy,
deletion, or induction of Treg. Here we summarize recent data regarding the in-vivo
induction of tolerogenic dendritic cells.
Chemicals
Vitamin D3—In-vivo administration of VD3 prevents dendritic cell maturation
independently of Toll like receptor (TLR) stimulation [54], and topically applied VD3
increases the suppressive capacity of Foxp3+ Treg in the draining lymph nodes [55].
Vitamin D analogs also prevent antigen-specific priming of alloreactive CD8+ T cells and
expands antigen-specific Foxp3+ Treg following immunization [56]. In transplantation,
pioneer studies of Deluca and colleagues demonstrated that in-vivo administration of VD3
markedly increases allograft survival in both murine and rat vascularized and
nonvascularized transplant models [57]. A possible explanation for this is that activation of
VD3 receptor reprograms dendritic cell maturation to differentiate them into tolerogenic
cells [58], which can be used in vivo to induce Treg-dependent antigen-specific
transplantation tolerance to murine islet allografts [59].
Aryl hydrocarbon receptor—In-vivo activation of aryl hydrocarbon receptor induces
antigen-specific long-term islet allograft acceptance by promoting Treg survival and
function [26].
Interleukins/cytokines
GM-CSF: In-vivo administration of mouse GM-CSF promoted the development of
CD11b+Gr-1+ myeloid-derived suppressor cells that prevent CD8+ T-cell-mediated immune
response [60]. Interestingly, GM-CSF promotes the expansion of specific myeloid derived
suppressor cell (MDSC) subsets in the spleen of tumor-bearing mice that were responsible
for tolerance [61].
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Delivering antigens specifically to DEC205 targets MHC class I T-cell responses, whereas
targeting dendritic cells via 33D1 preferentially modulates MHC class II T-cell responses
[62]. Lechler and colleagues have recently conjugated the 33D1 mAb with the Kd, which
deletes antigen-specific T cells, promotes Foxp3 Treg development, and induces indefinite
skin graft survival when combined with anti-CD8 mAb [63•].
Conclusion
There is a growing interest in taking dendritic cells into medicine [2]. The international
Society for Dendritic Cell and Vaccine Science has recently been created (http://www.dc-
vaccine.org/), and the next international symposium on dendritic cells will focus on the
importance of developing dendritic cell vaccines. Dendritic cell immunotherapy in
transplantation utilizes dendritic cells matured in vitro under specific culture conditions that
are injected intravenously later on as tolerogenic dendritic cells. This approach may not give
satisfactory results in transplantation simply because myeloid dendritic cells are poorly
specialized in migrating to the lymph nodes via high endothelial venules (HEVs) (reviewed
in [64]). This is of special interest, since Lakkis and colleagues [65] reported 10 years ago,
that the immune response to transplant antigens leading to graft rejection can be triggered in
the spleen and the lymph nodes. Therefore, we think that immunotherapy with dendritic
cells to induce antigen-specific transplantation must consider that tolerogenic dendritic cells
need to migrate the peripheral sites where antigen-specific T cells proliferate, namely the
spleen and the lymph nodes [66]. For nonvascularized skin transplants, we would like to
propose injections of ex vivo-matured tolerogenic dendritic cells in the skin, rather than into
blood, to augment the tolerogenic responses in specific skin draining lymph nodes. For
vascularized cardiac transplants, we would like to propose immunotherapy with blood-
circulating cells, such as CD8+DC, monocytes, and plasmacytoid dendritic cells (pDC),
which potentially control the immune response in the recipients’ lymph nodes and the
spleen. This is of special interest, since CD8+DC [67], monocytes [68], and pDC [69] have
been suggested to participate in Treg development, and novel approaches that target specific
dendritic cell subsets in vivo to promote indefinite skin allograft survival [63•]. Additionally,
it is possible that HEVs may need to be activated locally [70], or systemically [71,72] to
ensure efficient migration of specific dendritic cell subsets and their precursors to the lymph
nodes for successful immunotherapy, bearing in mind that these activators may affect the
release of potentially nonregulatory cytokines such as IL-6.
We also believe that a combination of donor and recipient dendritic cells may be necessary
to achieve indefinite allograft survival in transplantation. Acute rejection is mediated by
CD8+ and CD4+ T lymphocytes that recognize transplant antigens through the direct
pathway of allorecognition, whereas chronic rejection is mediated by CD4+T cells that
recognize transplant antigens through the indirect pathway of allorecognition [73,74]. In this
respect, Treg stimulated though both, the direct and indirect pathways of allorecognition
prevent acute and chronic rejection in recipient mice preconditioned with sublethal
irradiation following adoptive transfer [75], which suggest the potential use of Treg for
future cell-based immunotherapy in transplantation [76]. Therefore, it seems reasonable to
think that that a combination of donor dendritic cells that induce direct T-cell
hyporesponsiveness, and recipient dendritic cells that induce indirect T-cell
hyporesponsiveness and Treg development are both necessary for the induction of
transplantation tolerance using dendritic cell immunotherapy.
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